Citations

Clear

4207 citation(s) found for "Chen, Yu".

Cerebrospinal fluid proteomic signatures reveal APOE genotype-dependent lipid and immune profiles in cognitively unimpaired elderly
Bu, GuoJun, Ning, Zhiyuan, Lam, Jeff Y.L., Li, Zonghua , Martens, Yuka, Doss, Sydney V., Lageman, Senne B. , Vassilaki, Maria , Petersen, Ronald C., Tijms, Betty, Kanekiyo, Takahisa, Bu, Guojun , Doss, Sydney V. , Lam, Jeff Y L , Martens, Yuka A. , Doss, Sydney V , Tijms, Betty M , Kanekiyo, Takahisa , Bu, Guojun , Liu, Chia‐Chen , Heckman, Michael G. , Tijms, Betty M. , Kanekiyo, Takahisa

Mayo Clinic

No container title available | February 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8605807/v1 | PMID 41674829 Get It

Abstract Cerebrospinal fluid (CSF) proteomics offers insights into molecular changes in aging and Alzheimer’s disease (AD). Key AD biomarkers, in particular amyloid-β (Aβ) and tau, in CSF are strongly associated with APOE genotype, the strongest genetic risk determinant of AD. To investigate how APOE genotype influences CSF proteome across AD pathology and age, we analyzed 362 neurology-related proteins and established AD biomarkers in CSF from 145 cognitively unimpaired participants in the Mayo Clinic Study of Aging. Importantly, our cohort is uniquely balanced across APOE genotypes, with similar representation of APOE2 carriers, APOE3/3 genotype, and APOE4 carriers. We identified several proteins, including lipid metabolism-related Lp-PLA2 and immune-related ITGAM, with strong APOE genotype-specific association. Notably, meta-analysis confirmed that ITGAM levels were consistently higher in APOE4 compared to APOE2 carriers across multiple cohorts and proteomic platforms. In addition, with increasing amyloid deposition, APOE4 carriers exhibited stronger immune responses, reflected by elevated ITGAM, TNF-α receptors, and IL-6, whereas APOE2 carriers showed attenuated responses. We further observed sex-specific effects among APOE2 carriers, characterized by distinct patterns in amyloid and CXCL11 levels. These findings suggest distinct mechanisms underlying APOE2’s protective and APOE4’s detrimental effects in brain aging and AD, paving for personalized diagnostics and interventions.
Modified O-RADS Ultrasound Classification Using Qualitative Contrast-Enhanced Ultrasound Score for Borderline and Malignant Adnexal Lesions: An External Testing Study
Chen, Qingzi, Huang, Ju , Wu, Qiulin, Hong, Liangli , Chen, Shigao, Chen, Shaoqi , Chen, Zhe

Mayo Clinic

American Journal of Roentgenology | February 4, 2026 | Volume: 226 | Issue: 6 | Pages: No page available

10.2214/ajr.25.34326 | PMID 41636568 Get It

ITGB1 Regulates Triple‐Negative Breast Cancer Development by Modulating the Tumor Microenvironment
Song, Nuozi , Chen, Siqi, Wang, Lei , Dang, Jessica, Singh, Stephanie, Yang, Lu, Rosen, Steven T., Wang, Yingyu, Chen, Chun‐Wei D., Zhang, Cheng, Feng, Mingye , Chen, Chun‐Wei , Feng, Mingye , Chen, Chun-Wei , Dang, Jessica, Cao, Xu , Wang, Jinhui , Rosen, Steven T.

Mayo Clinic

Advanced Science | February 3, 2026 | Volume: 13 | Issue: 20 | Pages: No page available

10.1002/advs.202513672 | PMID 41632816 Get It

ABSTRACT Tumorigenesis and metastasis are frequently attributed to the intricate interplay between cancer cells and the tumor microenvironment (TME). Comprehending the mechanisms and key regulators of cancer‐immune crosstalk in the TME is imperative for developing efficacious immunotherapy. Through a series of in vivo CRISPR screens, we identified tumor‐intrinsic ITGB1 as a critical regulator of triple‐negative breast cancer (TNBC) development and deciphered its underlying mechanisms. Tumoral ITGB1 facilitated the establishment of pro‐tumorigenic TME by orchestrating tumor‐associated myeloid populations. Suppressing ITGB1 favored the enrichment of anti‐tumorigenic myeloid cells and enhanced infiltration of CD4 and CD8 T cells, culminating in superior antitumor effects. CRISPR scanning pinpointed a previously unrecognized functional domain essential for ITGB1's pro‐tumorigenic activity. This domain is distinct from all known ligand‐binding sites in ITGB1. An antibody capable of sterically blocking this domain significantly impaired TNBC progression. These findings position tumoral ITGB1 as a promising therapeutic target for reprogramming the TME from a pro‐ to an anti‐tumorigenic state, thereby effectively inhibiting TNBC development. Our study uncovers a novel mechanism of TNBC development and provides a unique therapeutic strategy for targeting ITGB1 in TNBC treatment.
Response to Letter to the Editor Regarding “New-Onset Psychiatric Disorders After Lumbar Fusion: Predictors, Timing, and Risk Stratification”
Ballatori, Alexander M. , Ton, Andy , Chen, Xiao T. , Buser, Zorica , Wang, Jeffrey, Ton, Andy , Buser, Zorica , Shahrestani, Shane

Mayo Clinic

Global Spine Journal | February 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/21925682251414155 | PMID 41631725 Get It

The TNFR superfamily member Fn14 impacts immunity and survival in experimental gliomas and response to immune checkpoint inhibitor therapy in glioblastoma patients
Kanvinde, Pranjali , Seas, Alexandra A. , McFarland, Emylee, Fang, Jennifer R. , Flick, M, Connolly, Nina P, Beniwal, Angad , Sharifai, Nima , Chen, Chixiang, Anastasiadis, Pavlos , Winkles, Jeffrey A. , Woodworth, Graeme F, Chen, Chixiang , Kanvinde, Pranjali P , Sharifai, Nima , Chen, Chixiang , Bar, Eli E , Winkles, Jeffrey A , Woodworth, Graeme F , Malla, Adarsha P. , Connolly, Nina P. , Yepes, Manuel A , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology Advances | February 3, 2026 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdag023 | PMID 41853810 Get It

Abstract Background Fibroblast growth factor-inducible 14 (Fn14) belongs to the TNFR superfamily. Fn14 overexpression can drive receptor-autonomous signaling, increase both cell invasion and tumor-associated macrophages/microglia (TAMMs) recruitment, and correlates with reduced survival in glioblastoma (GBM) patients and rat gliomas. While prior studies report Fn14 expression in non-tumor cells within the GBM tumor microenvironment (TME), their relative contributions to glioma pathobiology remain unclear. Methods Using tumor-host pairings of Fn14-positive and -knockout (-KO) cells and mice, we examined the role of Fn14 in glioma biology. Mouse glioma and human GBM datasets were analyzed at the cellular, protein, and transcriptomic levels to assess Fn14-associated changes in the glioma TME and survival outcomes. Results Fn14 was found to be highly expressed in tumor cells and TAMMs in human GBM and 2 well-characterized murine glioma models. Fn14 KO in both tumor and host cells increased overall survival. Notably, this survival benefit was greater in the glioma model characterized by a more immunologically activated TME. Immunophenotyping revealed that Fn14 loss reshapes the tumor-immune landscape, reducing the presence of immunosuppressive macrophages and exhausted T-cells, suggesting that Fn14 modulates both innate and adaptive immune responses. These findings were supported by analyses of human GBM datasets, where high Fn14 expression correlated with immunosuppressive shifts and poor patient responses to immune checkpoint inhibitor therapy. Conclusions This study provides the first description of the contributions of both tumor- and host-derived Fn14 expression to tumor immunity and survival and identifies Fn14 as an important mediator of innate and adaptive immune responses in gliomas.
Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer
Sarkar, Gobinda , Chen, Jun, Sood, Shubham , Fischer, K., Kossick, Kim, Schupack, Daniel , Graham, Rondell, Druliner, Brooke, Heydari, Zahra , Helgeson, Lauren, Garcia, Estela Cruz, Cawthon, Richard , Boardman, Lisa, Graham, Rondell P. , Garcia, Edwin , Fischer, Karen, Graham, Rondell P , Cruz Garcia, Estela Mariel , Chen, Jun, Druliner, Brooke R. , Boardman, Lisa

Mayo Clinic

Cancers | February 2, 2026 | Volume: 18 | Issue: 3 | Pages: 490

10.3390/cancers18030490 | PMID 41681962 Get It

Background and aims: Aberrations in telomere length can have important implications in cancer. Using a cohort of 1007 patients, we investigated whether leukocyte telomere length (LTL) in patients with colorectal cancer (CRC) is associated with survival. We also investigated whether some telomere maintenance genes are associated with survival in these patients. Methods: The Biobank for Gastrointestinal Health Research (BGHR), an ongoing project involving collection of biospecimens at the Mayo Clinic, was utilized to obtain data from patients diagnosed with stage II or III CRC. Blood samples were collected prior to chemotherapy/radiation and DNA was extracted for measuring median LTL. The main outcome measures were overall survival (OS) and disease-free survival (DFS) by disease stage. Results: A significant inverse relationship was observed with patient age and LTL (spearman correlation coefficient (r) = −0.48, 95%; p = 1.13 × 10−58). Females had significantly longer LTL than males (p = 3.97 × 10−5). The rs1317082 SNP in the TERC gene was significantly associated with both OS and DFS in combined stage II and stage III patients (p = 0.017 and p = 0.023, respectively). A statistically significant association of the OBFC1 SNP (rs9419958) was observed for OS for the combined stage II and stage III patients (p = 0.016). Importantly, LTL was significantly associated with both OS and DFS (p = 0.008 and 0.044 respectively) in combined stage II and stage III patients. Conclusions: Our results show that LTL is predictive of OS and DFS for stage II and III CRC patients, particularly over a longer follow-up, extending beyond five years after a diagnosis of CRC, and certain SNPs in genes involved in telomere maintenance are significantly associated with patient outcomes, independent of telomere length.
The association of osteoarthritis with the risk of de novo inflammatory arthritis in patients receiving immune checkpoint inhibitors: a retrospective study
Chen, S., Zhu, Xingxing, Zhang, Zhiqiang, Thanarajasingam, Uma , Crowson, Cynthia S, Zeng, Hu, Zeng, Hu , Zhu, Xingxing , Chen, Shiju, Zhu, Xingxing , Zeng, Hu , Crowson, Cynthia S.

Mayo Clinic

No container title available | January 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.28.26344880 | PMID 41646766 Get It

ABSTRACT Objective Identifying risk factors enables stratification of patients’ susceptibility to inflammatory arthritis immune-related adverse events (IA-irAE). This retrospective study examines whether preexisting osteoarthritis (OA) increases the likelihood of de novo IA in patients treated with immune checkpoint inhibitors (ICIs). Methods The prevalence of OA among ICI–treated patients who developed IA-irAE, those who developed other types of irAEs but not IA (non-IA irAE), and those who did not develop any irAEs (non-irAE) were compared. Electronic medical records were reviewed to extract demographic, clinical and laboratory data. Group comparisons and logistic regression analyses were performed. Results 181 de novo IA-irAE patients, 140 non-IA irAE patients and 170 non-irAE patients were included. The prevalence of OA was significantly higher in the IA-irAE group (69%) than the non-IA irAE group (48%) and the non-irAE group (48%) (both p < 0.001). The IA-irAE group demonstrated a higher frequency of multisite OA, with predominant hand involvement (62%) than the non-IA irAE with OA group (13%) and the non-irAE with OA group (13%) (both p < 0.001). A family history of autoimmune disease (AID) (OR 2.03, 95% CI 1.02–4.05), preexisting OA (OR 2.88, 95% CI 1.85–4.52) and melanoma (OR 2.63, 95% CI 1.56–4.47) were identified as risk factors for the development of IA-irAE. Conclusions OA was more prevalent among ICI-treated patients developing IA-irAE than those who did not. Hand OA was the most common OA pattern in IA-irAE patients. Preexisting OA, melanoma and a family history of AID were risk factors for IA-irAE.
PTEN-AKT2 Regulates Mixed Lineage Liver Cancer Development and Sensitizes Cancer Cells to TGFβ Treatment
Stiles, Bangyan, Tang, Qi , Slarve, Ielyzaveta, Chen, Jingyu , Zeng, Ni , Gu, Yiwei , He, Lina, Hu, Shunan , Alhousari, Diala, Xu, Zifei, Hua, Brittney , Zhang, G, Alba, Mario , Ji, Baoan , Chopra, Shefali , Kanel, Gary C., Yuan, Liyun, Slarve, Ielyzaveta, Chen, Jingyu, Zeng, Ni , He, Lina, Zhang, Guo , Nguyen, Phillip, Bharadwaj, Ajay, Lee, Jihyeon , Kreimer, Simion D. , Xu, Jian, Lu, Shelly C. , Eyk, Jennifer E. Van , Yuan, Liyun , Stiles, Bangyan L.

Mayo Clinic

No container title available | January 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8697220/v1 | PMID 41646383 Get It

Abstract Primary liver cancers, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), arise from the neoplastic transformation of hepatocytes and cholangiocytes, respectively. Loss or downregulation of PTEN, a tumor suppressor negatively regulating the PI3K/AKT pathway, is frequently observed in CCA and HCC. Notably, PTEN mutations are observed at nearly twice the frequency in combined CCA-HCC tumors than either HCC or CCA alone. Using lineage-specific liver-targeted PTEN-deficient mouse models, we demonstrate that PTEN loss drives cellular dedifferentiation and tumorigenesis, a process that is critically dependent on AKT2. Mechanistically, PTEN deficiency induces activation of NOTCH and upregulation of transcriptional factor SOX9, which plays a central role in tumor cell transformation. In parallel, PTEN loss increases SMAD4 expression and sensitizes the tumor cells to TGFβ signaling, with TGFβ treatment repressing SOX9 expression in tumor cells lacking PTEN. Together, our study defined a critical role for PTEN-AKT2 signaling in maintaining liver epithelial lineage fidelity and revealed how its disruption promotes the conversion of mature hepatocytes or cholangiocytes into liver cancer stem-like cells (LCSCs). Furthermore, we identify a PTEN-dependent crosstalk between NOTCH and TGFβ pathways that governs liver tumor development. Together, this work provides mechanistic insight into lineage plasticity in liver cancer with implications for pathway-directed therapy.
Heart–Brain Axis: Subclinical Cardiovascular Changes and Brain Health
Habibi, Parnian, Chen, Lin Yee, Sorond, Farzaneh A. , Shroff, Gautam R. , Sabayan, Behnam , Chen, Lin Y , Habibi, Parnian , Sorond, Farzaneh A.

Mayo Clinic

Journal of the American Heart Association | January 30, 2026 | Volume: 15 | Issue: 3 | Pages: No page available

10.1161/jaha.125.047458 | PMID 41614273 Get It

Complex bidirectional interactions between the nervous and cardiovascular systems are integrated through the heart–brain axis, a physiological pathway that governs both neural regulation of cardiovascular function and cardiovascular influences on brain health. Emerging evidence indicates that even in the absence of overt disease, subclinical changes in the heart, aortic arch, and extracranial arteries contribute to brain injury and cognitive vulnerability. This review synthesizes current knowledge on how subclinical heart–brain axis dysfunction affects brain structure and function, highlighting the roles of central and autonomic neural pathways as well as hormonal signaling in driving neurological decline. Key biomarkers linked to silent brain injury, cognitive decline, and dementia are discussed, emphasizing their potential for early risk stratification and as targets for preventive interventions. We also outline mechanistic pathways connecting subclinical heart–brain axis dysfunction to adverse brain outcomes, identify major gaps in current evidence, and propose priorities for future research and clinical trials aimed at early detection and risk reduction to preserve brain health.